How sustainability practices may positively impact business operations europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.
FDA approves expanded use for Chiesi’s sickle cell drug Ferriprox
Iron-chelating agent approved for the treatment of transfusional iron overload due to SCD or other anaemias
Italy’s Chiesi Global Rare Diseases has gained approval from the US Food and Drug Administration (FDA) for the expanded use of its sickle cell disease (SCD) treatment Ferriprox.
Ferriprox (deferiprone) is now approved in the US for the treatment of transfusional iron overload due to SCD or other anaemias in adult and paediatric patients aged three years or older.
The new approval expands the use of Ferriprox beyond its other indication, where it is approved to treat patients with transfusional iron overload due to thalassemia syndromes.
Published: May 01, 2021
Expanded indications for patients with sickle cell disease or other anemias, as well as thalassemia
BOSTON, May 1, 2021 /PRNewswire/ Chiesi Global Rare Diseases, a business unit of
Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), announced today that the U.S. Food & Drug Administration (FDA) has approved FERRIPROX
® (deferiprone) for the treatment of transfusional iron overload due to sickle cell disease (SCD) or other anemias in adult and pediatric patients 3 years of age and older. This FDA approval expands the use of FERRIPROX for patients with SCD or other anemias as well as patients with thalassemia regardless of prior iron chelation exposure.
FDA Expands Approval of Chiesi’s Ferriprox for Transfusional Iron Overload due to Sickle Cell Disease
Share
Rare Daily Staff
The U.S. Food and Drug Administration expanded the approval of Chiesi Global Rare Diseases’ Ferriprox for the treatment of patients with transfusional iron overload due to sickle cell disease or other anemias in adults and children age 3 and older.
This FDA approval expands the use of Ferriprox for patients with sickle cell disease or other anemias, as well as patients with thalassemia, regardless of prior iron chelation exposure.
Sickle cell disease (SCD) affects about 100,000 people in the United States and leads to a lower life expectancy by more than 20 years compared to the general population. SCD patients are typically diagnosed prior to 2 years of age and the more severe patients start to experience pain crises early in childhood. Many require hospitalization and chronic blood transfusions to manage disease complications. Disease